Oxford Biomedica has confirmed the appointment of Lucinda Crabtree to the role of chief financial officer (CFO) and board member.

Crabtree was previously at MorphoSys AG where she served as CFO, leading a finance team across the US and Germany until the company's acquisition by Novartis.

She has previously been a CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company, and also has experience from the investment and banking sectors having held roles at institutions including Woodford Investment Management, Goldman Sachs, and Jefferies.

“I am excited to be joining Oxford Biomedica as CFO today,” Crabtree said. “I firmly believe in the company’s growth strategy and am looking forward to working with the board and the rest of the leadership team. Together, I’m confident we will fulfil our mission of enabling our growing client base to deliver life-changing therapies to patients.”

Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines.

The group’s CEO, Frank Mathias, added: “We are thrilled that Lucy has joined Oxford Biomedica as our new CFO and Board member today. Lucy brings a wealth of experience from her roles as a CFO and time as a healthcare investor and equity research analyst. Her experience will be invaluable as we grow our international position as a leading cell and gene therapy CDMO.”

---